Table 2.
The associations between patient characteristics and p‐mTOR or p‐S6 expression levels in cohort 1 and cohort 2
| Cohort 1 | p‐mTOR expression | p‐S6 expression | ||||
|---|---|---|---|---|---|---|
| Low (<score 6) | High (≥score 6) | P | Low (<score 3) | High (≥score 3) | P | |
| N = 15 | N = 83 | N = 39 | N = 59 | |||
| Agea, y (range) | 62 (58‐66) | 63 (57‐70) | .870 | 63 (58‐70) | 63 (57‐69) | .799 |
| Sex (Male) | 12 (80%) | 47 (57%) | .088 | 31 (79%) | 28 (47%) | .002a |
| Distance from AV (<4 cm) | 12 (80%) | 49 (59%) | .123 | 28 (72%) | 33 (56%) | .113 |
| pT (T1/T2/T3/T4) | 2/5/7/1 | 9/25/42/7 | .977 | 2/13/20/4 | 9/17/29/4 | .445 |
| pN (positive) | 4 (27%) | 19 (23%) | .751 | 8 (21%) | 15 (25%) | .575 |
| LVI (positive) | 6 (40%) | 51 (61%) | .121 | 23 (59%) | 34 (58%) | .895 |
| Histological type (differentiated) | 1 (7%) | 6 (7%) | .938 | 2 (5%) | 5 (8%) | .529 |
| TRG (responder) | 8 (53%) | 28 (34%) | .075 | 10 (26%) | 26 (44%) | .128 |
| Cohort 2 | N = 27 | N = 53 | N = 29 | N = 51 | ||
|---|---|---|---|---|---|---|
| Age,a y (range) | 69 (59‐75) | 64 (55‐72) | .192 | 68 (55‐78) | 64 (56‐74) | .911 |
| Sex (male) | 1 (4%) | 29 (55%) | .481 | 15 (52%) | 31 (61%) | .431 |
| Location (rectum) | 4 (15%) | 10 (19%) | .652 | 7 (24%) | 7 (14%) | .239 |
| pT (T2/T3/T4) | 3/19/5 | 7/32/14 | .666 | 4/20/5 | 6/31/14 | .587 |
| pN (positive) | 17 (63%) | 20 (38%) | .032a | 13 (45%) | 24 (47%) | .847 |
| LVI (positive) | 22 (81%) | 39 (74%) | .433 | 22 (76%) | 39 (77%) | .951 |
| Histological type (Differentiated) | 26 (96%) | 50 (94%) | .704 | 27 (93%) | 49 (96%) | .557 |
Abbreviations: AV, anal verge; Differentiated, well to moderately differentiated adenocarcinoma; Location, Location of primary tumor; LVI, lymphovascular invasion; p‐mTOR expression level, phosphorylated mammalian target of rapamycin expression level based on the results of immunohistochemical staining; pN stage, pathological lymph node metastasis; pN, pathological lymph node metastasis; p‐S6 expression level, phosphorylated S6 ribosomal protein expression level based on the result of immunohistochemical staining; pT, pathological T stage; pT, pathological T stage; TRG, tumor regression grade.
a
Data are expressed as median (range).